

Inpatient Support Program (gMG) Terms & Conditions (T&Cs)

The Alexion OneSource™ Inpatient Support for gMG Program (“Program”) is a voluntary support program offered by Alexion Pharmaceuticals, Inc. (“Alexion”) to help patients who have a physician-determined urgent medical need to initiate ULTOMIRIS® (ravulizumab-cwvz) (“Product”) in an inpatient setting. The Program provides up to three dispenses of Product free of charge to eligible patients. The Program does not assist with any infusion-related costs.

All patients, healthcare providers, healthcare settings, and dispensers who participate in the Program (collectively, “Users”) must accept and abide by these terms and conditions (the “Terms”).

Eligibility: Patients are eligible for the Program if they meet ALL the following criteria:

- Are enrolled in OneSource, a personalized patient support program offered by Alexion
 - In the event the patient/caregiver/healthcare proxy is unable to sign the OneSource patient consent form at the time of program enrollment, Alexion reserves the right to authorize the dispensing of one dose of ULTOMIRIS under circumstances of medical urgency at the request of the physician. This is contingent upon the understanding that the patient/caregiver/healthcare proxy will sign the OneSource patient consent for enrollment into OneSource within five (5) business days of dispensing product. No further medication will be dispensed without a signed patient consent form.
 - If a patient/caregiver/healthcare proxy declines to sign a patient consent, no further medication will be dispensed under the Program, and the patient will be discharged from the Program.
- Reside and receive treatment in the United States or its territories
- Have a prescription/medication order for the Product and be an adult with anti-AChR antibody-positive generalized myasthenia gravis
- Have a medically urgent need to initiate the Product in an inpatient setting, as determined by a healthcare provider
- Have commercial insurance and are not beneficiaries or recipients of any federal, state, or government-funded healthcare program, including Medicaid, Medicare (including Medicare Part D), Medicare Advantage Plans, Medigap, Veterans Affairs, Department of Defense or TRICARE, or other federal or state programs (including any state prescription drug assistance programs)
- Are not taking any C5-inhibitor therapies at the time of Program initiation
- To remain eligible to receive free Product through the Program following discharge to an outpatient setting, Users must initiate any procedures required by the payer (eg, request prior authorization) and must be awaiting a final payer coverage decision

Participation Rules: To enroll in the Program, Users must provide documentation demonstrating eligibility and any other information requested by OneSource and update OneSource of any changes in insurance coverage (eg, approval of a prior authorization) and/or expected site-of-care transitions. Users are responsible for complying with all obligations or requirements set forth by their insurer(s). Users may not seek or obtain coverage or reimbursement for the free Product provided through the Program, directly or indirectly, from any other party, including from the patient, third-party payer, or any government healthcare program. The Product may not be sold, resold, traded, distributed for sale, or returned for credit.

Additional Terms and Disclosures: The Program is not a health insurance or a benefit plan, nor does it obligate the prescription, use, or recommendation of any specific medication, healthcare provider, or healthcare setting. Participation in the Program is not conditioned on any past, present, or future purchase

Inpatient Support Program (gMG) Terms & Conditions (T&Cs)

of the Product or any other Alexion product. This is a voluntary program. Patients may choose not to enroll in the Program and may still receive the Product. Patients may participate in OneSource without participating in the Program. After enrolling in the Program, patients may opt out at any time by contacting OneSource. Alexion reserves the right to rescind, revoke, or amend the Program and these Terms without notice. Alexion further reserves the right to terminate any User's participation in the Program if Alexion determines in its sole discretion that they have not complied with any of these Terms.

If during the program approval time frame, Alexion is made aware a participating patient is a beneficiary or recipient of any federal, state, or government-funded healthcare program, including Medicaid, Medicare (including Medicare Part D), Medicare Advantage Plans, Medigap, Veterans Affairs, Department of Defense or TRICARE, or other federal or state programs (including any state prescription drug assistance programs), **the hospital will be responsible** for reimbursing Alexion the cost of the Product that was provided free of charge.

Additional Healthcare Provider, Healthcare Setting, and Dispenser Terms and Disclosures:

- Participating healthcare providers, healthcare settings, and dispensers each must hold a valid license under applicable laws. Both the prescriber and the dispenser must be REMS-certified.
- The Product must first be administered in an inpatient setting to eligible patients who have an urgent medical need to initiate the Product pursuant to a valid prescription from a licensed provider and in compliance with REMS requirements.
- After the initial loading dose, the Program can provide up to two additional dispenses of the Product free of charge to eligible patients. Accordingly, an individual patient may receive no more than three dispenses of Product through the Program.
- Upon completion of enrollment (which consists of patient enrollment in OneSource, OneSource verifying eligibility, prescribers completing the Inpatient Support Program Form, and healthcare setting agreement to these Terms), participating healthcare settings will be eligible to order the Product.
- Participating healthcare settings must have adequate controls to track utilization of the Product and must establish adequate controls to ensure that the Product is appropriately segregated, dispensed, and tracked to ensure compliance with these Terms. For each order, the participating healthcare setting certifies and acknowledges the following:
 - It maintains adequate controls to track utilization of the Product, including maintaining Product separate from any commercially purchased units of ULTOMIRIS and tracking the number of units of the Product dispensed since last order and the associated dispense date/month;
 - The participating patient begins the Product in an inpatient setting, and no patient has received more than three dispenses of the Product;
 - It has not and will not seek reimbursement for any Product; and
 - It has or will appropriately document that the Product was free in any reimbursement request
- Healthcare settings understand that the Product is commercially labeled and not labeled as samples or free drug but that they must treat the Product as free product in accordance with these Terms.
- Program participant names and the free Product disbursements may be reported as required by applicable laws. Once reported, this information may be made publicly available.